Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Minireview – Adsorption Technologies

Is There a Future for Adsorption Techniques in Sepsis?

Stegmayr B.G.

Author affiliations

Department of Internal Medicine, University Hospital Umeå, Sweden

Related Articles for ""

Blood Purif 2000;18:149–155

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Minireview – Adsorption Technologies

Published online: August 03, 2000
Issue release date: 2000

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 5

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

During sepsis toxins released from, e.g., bacteria induce reactions of various cascade systems that may cause progression of the patient into septic shock, disseminated intravascular coagulation, multiorgan dysfunction syndrome and subsequent death. The use of conventional treatments using antibiotics, fluid substitution, inotropic drugs, respiration aid and dialysis is not enough to reverse the serious prognosis. The addition of various other drugs such as antibodies against various cytokines and cytokine receptors, pentoxiphylline, immunoglobulins or high doses of steroids is usually without benefit for the prognosis of the patient. Another possibility to reduce the extent of toxins and other harmful compounds in the circulation is the use of apheresis (removal by technical devices). This can be done either in a nonselective way (plasma exchange, plasmapheresis) or more selectively using various adsorbers such as polymyxin B. The survival in studies varies between 50 and 80%. Besides the use of nonselective apheresis, the development of various selective adsorption techniques may be one approach to improve survival of these severely ill patients.

© 2000 S. Karger AG, Basel


References

  1. Vincent JL: Definition and pathogenesis of septic shock. Curr Top Microbiol Immunol 1996;216:1–13.
    External Resources
  2. Brandtzaeg P: Significance and pathogenesis of septic shock. Curr Top Microbiol Immunol 1996;216:15–37.
  3. Rietschel ET, Brade H, Holst O, Brade L, Müller-Loennies S, Mamat U, Zähringer U, Beckmann F, Seydel U, Brandenburg K, Ulmer AJ, Mattern T, Heine H, Schletter J, Loppnow H, Schönbeck U, Flad H-D, Hauschildt S, Schade UF, DiPadova F, Kusumoto S, Schumann RR: Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol 1996;216:39–81.
  4. Rietschel ET, Wagner H (eds): Pathology of septic shock. Curr Top Microbiol Immunol 1996;216.
  5. Bone RC, Sprung CL, Sibbald WJ: Definitions for sepsis and organ failure. Crit Care Med 1992;20:724–726.
  6. Blombäck M, Eklund J, Hellgren M, Lagerkranser M, Swedenbord J: Blood coagulation and fibrinolytic factors as well as their inhibitors in trauma. Scand J Clin Lab Invest 1985;45(suppl 178):15–23.
  7. Bang NU: Diagnosis and management of bleeding disorders; in Ayres SM (ed): Textbook of Critical Care, ed 3. London, Saunders, 1995, pp 1324–1334.
  8. Dofferhoff AS, de Jong HJ, Bom VJ, van der Meer J, Limburg PC, de Vries Hospers HG, Marrink J, Mulder PO, Weits J: Complement activation and the production of inflammatory mediators during the treatment of severe sepsis in humans. Scand J Infect Dis 1992;24:197–204.
    External Resources
  9. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125–1128.
  10. Bone RC: Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125:680–687.
  11. Zumla A: Superantigens, T cells, and microbes. Clin Infect Dis 1992;15:313–320.
  12. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24:1431–1440.
  13. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771–783.
  14. Reinhart K, Wiegand LC, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomised, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733–742.
  15. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697–1702.
  16. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomised, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836–1843.
  17. Knaus WA, Harrell FJ, LaBrecque JF, Wagner DP, Pribble JP, Draper EA, Fisher CJ, Soll L: Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996;24:46–56.
  18. Werdan K: Supplemental immune globulins in sepsis. Clin Chem Lab Med 1999;37:341–349.
  19. Baudo F, Caimi TM, de CF, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, Rossi R, D’Angelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G: Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomised, multicenter study. Intens Care Med 1998;24:336–342.
  20. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P: Effect of pentoxifylline in severe sepsis: Results of a randomised, double-blind, placebo-controlled study. Arch Surg 1998;133:94–100.
  21. Slotman GJ, Fisher CJ, Bone RC, Clemmer TP, Metz CA: Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1993;21:191–195.
  22. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ: Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430–1439.
  23. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645–650.
  24. Koukline V, Utrobin U, Busund R, Nedashkovsky E: Analysis of efficiency of plasmapheresis in treatment of severe sepsis and septic shock: A prospective, randomised, clinical trial (abstract). 2nd Int Congr Int Soc for Apheresis, Saarbrücken, 1999, p 109.
  25. Stegmayr B, Tärnvik A: Complement activation in plasma exchange by single filtration and centrifugation and in cascade filtration. Blood Purif 1989;7:10–15.
    External Resources
  26. Falkenhagen D, Brown GS, Boettcher M, Falkenhagen U, Schmidt B, Gurland HJ, Klinkmann H: Permeation of complement factors through high-flux dialyzers and plasma separation membranes; in Bambauer R, Malchesky PS, Falkenhagen D (eds): Therapeutic Plasma Exchange and Selective Plasma Separation. Stuttgart, Schattauer, 1987, pp 215–222.
  27. Kotitschke R, Borberg H, Güsken G: Long-term study of the protein profiles in healthy volunteers after plasma exchange; in Bambauer R, Malchesky PS, Falkenhagen D (eds): Therapeutic Plasma Exchange and Selective Plasma Separation. Stuttgart, Schattauer, 1987, pp 199–204.
  28. Tani T, Hanasawa K, Endo Y, Yoshioka T, Kodama M, Kaneko M, Uchiyama Y, Akizawa T, Takahasi K, Sugai K: Therapeutic apheresis for septic patients with organ dysfunction: Hemoperfusion using a polymyxin B immobilized column. Artif Organs 1998;22:1038–1044.
  29. Tani T, Hanasawa K, Kodama M, Imaizumi H, Yonekawa M, Saito M, Ikeda T, Yagi Y, Takayama K, Amano I, Shimaoka H, Ohta M, Katayama H, Okahisa T, Kato M, Koga N, Fujita N: Correlation between plasma endotoxin, plasma cytokines and plasminogen activator inhibitor-1 activities in septic patients (abstract). Ther Apher 1999;3:143.
  30. Kanesaka S, Ogata H, Akizawa T, Takahashi Y: Effect of endotoxin adsorption with polymyxin B immobilized fibre on hemodynamics in severe sepsis (abstract). Ther Apher 1999;3:124.
  31. Brun Buisson C, Doyon F, Carlet J: Bacteremia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996;154:617–624.
  32. Leibovici L, Drucker M, Konigsberger H, Samra Z, Harrari S, Ashkenazi S, Pitlik SD: Septic shock in bacteremic patients: Risk factors, features and prognosis. Scand J Infect Dis 1997;29:71–75.
  33. Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, Montani C, Magni E: The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intens Care Med 1995;21(suppl):244–249.
  34. Karnik AM, Bashir R, Khan FA, Carvounis CP: Renal involvement in the systemic inflammatory reaction syndrome. Ren Fail 1998;20:103–116.
  35. Strutz F, Heller G, Krasemann K, Krone B, Muller GA: Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intens Care Med 1999;25:435–444.
  36. Bossink AW, Groeneveld J, Hack CE, Thijs LG: Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria? Chest 1998;113:1533–1541.
  37. Martinez MA, Pena JM, Fernandez A, Jimenez M, Juarez S, Madero R, Vazquez JJ: Time course and prognostic significance of hemostatic changes in sepsis: Relation to tumor necrosis factor-alpha. Crit Care Med 1999;27:1303–1308.
  38. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351:929–933.
  39. Schoenberg MH, Weiss M, Radermacher P: Outcome of patients with sepsis and septic shock after ICU treatment. Langenbecks Arch Surg 1998;383:44–48.
  40. Jardin F, Fourme T, Page B, Loubieres Y, Vieillard-Baron A, Beauchet A, Bourdarias JP: Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. Chest 1999;116:1354–1359.
  41. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ: Acute renal failure in intensive care units–causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996;24:192–198.
  42. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P: Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 1996;11:293–299.
  43. Barretti P, Soares VA: Acute renal failure: Clinical outcome and causes of death. Ren Fail 1997;19:253–257.
  44. Chertow GM, Lazarus JM, Paganini EP, Allgren RL, Lafayette RA, Sayegh MH: Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 1998;9:692–698.
  45. Kresse S, Schlee H, Deuber HJ, Koall W, Osten B: Influence of renal replacement therapy on outcome of patients with acute renal failure. Kidney Int Suppl 1999;72:75–78.
  46. Fiaccadori E, Lombardi M, Leonardi S, Rotelli CF, Tortorella G, Borghetti A: Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: A prospective cohort study. J Am Soc Nephrol 1999;10:581–593.
  47. Cosentino F, Chaff C, Piedmonte M: Risk factors influencing survival in ICU acute renal failure. Nephrol Dial Transplant 1994;4:179–182.
  48. Hakim RM, Wingard RL, Parker RA: Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994;331:1338–1342.
  49. Chertow GM, Christiansen CL, Cleary PD, Munro C, Lazarus JM: Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 1995;155:1505–1511.
  50. Bhandari S, Turney JH: Survivors of acute renal failure who do not recover renal function. Q J Med 1996;89:415–421.
  51. Jorres A, Gahl GM, Dobis C, Polenakovic MH, Cakalaroski K, Rutkowski B, Kisielnicka E, Krieter DH, Rumpf KW, Guenther C, Gaus W, Hoegel J: Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: A prospective randomised multicentre trial. International Multicentre Study Group. Lancet 1999;354:1337–1341.
  52. Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Zandstra DF: Outcome of critically ill patients treated with intermittent high-volume haemofiltration: A prospective cohort analysis. Intens Care Med 1999;25:814–821.
  53. Swartz RD, Messana JM, Orzol S, Port FK: Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Am J Kidney Dis 1999;34:424–432.
  54. Frost L, Pedersen RS, Hansen HE: Prognosis in septicemia complicated by acute renal failure requiring dialysis. Scand J Urol Nephrol 1991;25:307–310.
  55. Bjorvatn B, Bjertnaes L, Fadnes HO, Flaegstad T, Gutteberg TJ, Kristiansen B-E, Pape J, Rekvig OP, Østerud B, Aanderud L. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J 1984;288:439–441.
  56. Brandtzaeg P, Sirnes K, Folsland B, Godal HC, Kierulf P, Bruun JN, Dobloug J: Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis. Preliminary data on eight patients. Scand J Clin Lab Invest 1985;178(suppl):53–55.
  57. Graf N, Bambauer R, Limbach HG: Indications, application and appraisal of therapeutic plasma exchange in children; in Bambauer R, Malchesky PS, Falkenhagen D (eds): Therapeutic Plasma Exchange and Selective Plasma Separation. Stuttgart, Schattauer, 1987, pp 267–273.
  58. Häuser W, Christmann F-J, Klein T, Traut G: Therapeutic plasma exchange in septic shock; in Bambauer R, Malchesky PS, Falkenhagen D (eds): Therapeutic Plasma Exchange and Selective Plasma Separation. Stuttgart, Schattauer, 1987, pp 287–293.
  59. Stegmayr BG, Wirell M: Reversal of advanced disseminated intravascular coagulation with uremia by plasma exchange; in Bambauer R, Malchesky PS, Falkenhagen D (eds): Therapeutic Plasma Exchange and Selective Plasma Separation. International Symposium, Homburg/Saar, 1985. Stuttgart, Schattauer, 1987, pp 133–136.
  60. Asanuma Y, Takahashi T, Koyama K, Kato T, Omokawa S, Sueoka A, Tanaka J: Exchange blood transfusion and on-line plasma exchange for sepsis in infants. ASAIO Trans 1989;35:343–345.
    External Resources
  61. Stegmayr B, Berseus O, Björsell-Östling E, Wirell M: Plasma exchange in patients with severe consumption coagulopathy and acute renal failure. Transfus Sci 1990;11:271–277.
  62. McClelland P, Williams PS, Yaqoob M, Mostafa SM, Bone JM: Multiple organ failure: A role for plasma exchange? Intens Care Med 1990;16:100–103.
  63. van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LF, van der Meer JW: Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992;15:424–430.
  64. Gårdlund B, Sjoelin J, Nilsson A, Roll M, Wickerts CJ, Wikström B, Wretlind B: Plasmapheresis in the treatment of primary septic shock in humans. Scand J Infect Dis 1993;25:757–761.
  65. Stegmayr BG, Jakobson S, Rydvall S, Björsell-Östling S: Plasma exchange in patients with acute renal failure in the course of multiorgan failure. Int J Artif Organs 1995;18:45–52.
  66. Stegmayr BG, Norda R, Banga R, Rydvall A: Plasma exchange may improve survival of patients with multiorgan dysfunction syndrome including acute renal failure (abstract). Ther Apher 1999;3:141.
  67. Reeves JH, Butt WW, Shann F and The Melbourne Plasmafiltration in Sepsis Study Group: A randomised controlled trial of continuous plasmafiltration in sepsis. Published Internet mode: www.invivo.net/CRRT96/sepsisHFC96.html.
  68. von Appen K, Weber C, Losert U, Schima H, Gurland HJ, Falkenhagen D: Microspheres based detoxification system: A new method in convective blood purification. Artif Organs 1996;20:420–425.
  69. Weber C, Henne B, Loth F, Schoenhofen M, Falkenhagen D: Development of cationically modified cellulose adsorbents for the removal of endotoxins. ASAIO J 1995;41:M430–M434.
    External Resources
  70. Mitteregger R, White A, Weber C, Rossmanith E, Mohr T, Micksche M, Falkenhagen D: In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment. Ther Apher 1999;3:257–263.
  71. Ash SR, Levy H, Steczko J, Carr DJ, Blake DE: Push-pull sorbent-based pheresis (Biologic-DTPF system) in treatment of systemic inflammatory response syndrome (SIRS) (abstract). Ther Apher 1999;3:113.
  72. Samtleben W, Bengsch S, Boos KS, Seidel D: HELP apheresis in the treatment of sepsis. Artif Organs 1998;22:43–46.
  73. Zimmermann M, Busch K, Kuhn S: Zeppezauer M: Endotoxin adsorbent based on immobilized human serum albumin. Clin Chem Lab Med 1999;37:373–379.
  74. Bambauer R: Therapeutischer Plasmaaustausch und verwandte Plasmaseparationsverfahren. Stuttgart, Schattauer, 1988.

Article / Publication Details

First-Page Preview
Abstract of Minireview – Adsorption Technologies

Published online: August 03, 2000
Issue release date: 2000

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 5

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.